CHEK2 Alterations in Pediatric Malignancy: A Single-Institution Experience
暂无分享,去创建一个
Nilay Shah | A. Audino | K. Schieffer | K. Zajo | E. Abdelghani | Catherine E. Cottrell | Catherine Cottrell | Catherine E Cottrell | Kristin N Zajo
[1] R. Scott,et al. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants , 2022, Journal of the National Cancer Institute.
[2] L. Godley,et al. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies , 2022, Current Hematologic Malignancy Reports.
[3] H. van Attikum,et al. CHEK2 variants: linking functional impact to cancer risk. , 2022, Trends in cancer.
[4] E. V. Van Allen,et al. Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes , 2022, American journal of human genetics.
[5] Xueen Li,et al. The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation , 2022, Frontiers in Genetics.
[6] A. Sokolenko,et al. Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability , 2022, Breast Cancer Research and Treatment.
[7] H. Takada,et al. Cancer-Predisposition Genetic Analysis in Children with Brain Tumors Treated at a Single Institution in Japan , 2021, Oncology.
[8] R. Eeles,et al. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk , 2021, Cancer research.
[9] E. Sokol,et al. Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] J. M. Fernández,et al. Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care , 2021, Cancers.
[11] P. Leavey,et al. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report , 2021, Journal of Clinical Oncology.
[12] A. Stenman,et al. Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma , 2021, Endocrine-related cancer.
[13] P. Pelicci,et al. Machine learning-based reclassification of germline variants of unknown significance: The RENOVO algorithm. , 2021, American journal of human genetics.
[14] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[15] A. Goldenberg,et al. Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma , 2021, JCO precision oncology.
[16] P. Kleiblova,et al. CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate , 2020, Cells.
[17] L. Forétova,et al. Identification of Germline Mutations in Melanoma Patients with Early Onset, Double Primary Tumors, or Family Cancer History by NGS Analysis of 217 Genes , 2020, Biomedicines.
[18] C. Lázaro,et al. Comprehensive analysis and ACMG‐based classification of CHEK2 variants in hereditary cancer patients , 2020, Human mutation.
[19] Samantha N. McNulty,et al. Pediatric meningioma: a clinicopathologic and molecular study with potential grading implications , 2020, Brain pathology.
[20] P. Cin,et al. Malignant tumours of the uterus and ovaries with Mullerian and germ cell or trophoblastic components have a somatic origin and are characterised by genomic instability , 2020, Histopathology.
[21] G. Vassal,et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. , 2020, The New England journal of medicine.
[22] F. Cheng,et al. Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors , 2020, Nature Communications.
[23] F. Zaker,et al. Epigenetic changes in FOXO3 and CHEK2 genes and their correlation with clinicopathological findings in myelodysplastic syndromes. , 2020, Hematology/oncology and stem cell therapy.
[24] A. Chiriță-Emandi,et al. Challenges in reporting pathogenic/potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels , 2020, Scientific Reports.
[25] Ryan L. Collins,et al. The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.
[26] J. Biegel,et al. Germline genetic landscape of pediatric central nervous system (CNS) tumors. , 2019, Neuro-oncology.
[27] D. Kodetová,et al. Somatic genetic alterations in a large cohort of pediatric thyroid nodules , 2019, Endocrine connections.
[28] A. Papavassiliou,et al. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system , 2019, Human mutation.
[29] J. Reis-Filho,et al. The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers , 2019, JNCI cancer spectrum.
[30] P. Stadler,et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma , 2019, Nature Communications.
[31] James R. Anderson,et al. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.
[32] V. Menon,et al. Factors predicting reclassification of variants of unknown significance. , 2018, American journal of surgery.
[33] P. Radice,et al. Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of CHEK2 in Wilms tumour susceptibility , 2018, Oncotarget.
[34] M. Czyżewska,et al. Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML. , 2018, Leukemia research.
[35] Colin C Pritchard,et al. Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations , 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[36] C. Vnencak-Jones,et al. The impact of variant classification on the clinical management of hereditary cancer syndromes , 2018, Genetics in Medicine.
[37] Michael C. Heinold,et al. The landscape of genomic alterations across childhood cancers , 2018, Nature.
[38] S. Gruber,et al. Germline Genetic Features of Young Individuals With Colorectal Cancer. , 2017, Gastroenterology.
[39] James M Ford,et al. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk , 2017, Genetics in Medicine.
[40] R. Davis,et al. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. , 2017, Blood.
[41] Qing-Rong Chen,et al. A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor , 2017, Nature Genetics.
[42] T. Merchant,et al. Results of COG ACNS0331: A Phase III Trial of Involved-Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with Chemotherapy in Average-Risk Medulloblastoma: A Report from the Children's Oncology Group , 2016 .
[43] Tao Wang,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[44] J. Mora,et al. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression , 2016, Oncotarget.
[45] Li Ding,et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.
[46] P. Souček,et al. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma , 2015, PloS one.
[47] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[48] J. Biegel,et al. Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. , 2014, Cancer genetics.
[49] G. Gao,et al. Genetic association of CHEK2, GSTP1, and ERCC1 with glioblastoma in the Han Chinese population , 2014, Tumor Biology.
[50] Nazneen Rahman,et al. Realizing the promise of cancer predisposition genes , 2014, Nature.
[51] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[52] Steven J. M. Jones,et al. The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.
[53] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[54] Mark D. Johnson,et al. Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma. , 2012, Neoplasia.
[55] N. Pavletich,et al. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. , 2009, Molecular cell.
[56] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[57] Jiri Bartek,et al. An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.
[58] Patricia L. Harris,et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts , 2007, International journal of cancer.
[59] Johanna Schleutker,et al. CHEK2 mutations in primary glioblastomas , 2005, Journal of Neuro-Oncology.
[60] Y. Hayashi,et al. Aberrations of the CHK2 gene are rare in pediatric solid tumors. , 2005, International journal of molecular medicine.
[61] J. Lubiński,et al. CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.
[62] H. Piwnica-Worms,et al. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. , 2003, Molecular cancer research : MCR.
[63] E. Appella,et al. Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription , 2002, The EMBO journal.
[64] M. Nakanishi,et al. Role of Human Cds1 (Chk2) Kinase in DNA Damage Checkpoint and Its Regulation by p53* , 1999, The Journal of Biological Chemistry.